The team’s starting point was a systematic survey of how the human striatum changes with age. Rather than focusing narrowly on the canonical disease genes, the researchers examined global patterns of gene expression in human striatal tissue and found something striking: an age-dependent upregulation of translation-related genes, the molecular machinery that ribosomes use to build proteins from messenger RNA templates. Among the genes climbing with age was PPP1R15B, abbreviated R15B, a regulator of protein synthesis that belongs to a conserved family of stress-responsive translation controllers. In other words, one of the deepest molecular signatures of an aging striatum is a gradual turning up of the dial that governs how much protein cells make—a change that, in a brain already burdened with a misfolding-prone mutant protein, could be far from benign.

The logic of why this matters comes down to proteostasis, the cell’s tightly balanced system for producing, folding, and clearing proteins. Neurons are among the longest-lived cells in the body and cannot dilute toxic protein clumps by cell division, so they depend exquisitely on keeping protein synthesis under control. Mutant huntingtin is known to disrupt this balance, and recent work from other groups has implicated polyglutamine-mediated ribotoxicity—stress inflicted on the protein-making machinery itself—in Huntington’s pathology. The new findings place R15B squarely in this arena. As its expression rises with age in the striatum, the cell’s capacity to rein in translation may erode, allowing the mutant protein and the stress it generates to accumulate past a tipping point. Aging, in this view, is not just the passage of time but an active physiological process that remodels the disease landscape.

To test whether R15B is merely a bystander or an active participant, the researchers turned to pharmacology. Raphin1, a selective inhibitor of R15B developed through earlier work on translation-control pathways, was administered to HD YAC128 mice, a widely used model that carries the human mutant HTT gene. The results were notable on two fronts: the compound rescued early learning deficits and also alleviated late-stage motor impairments in the animals. That dual rescue spans both cognitive and motor domains of the disease, suggesting that dampening excessive protein synthesis can meaningfully alter functional outcomes in a living organism carrying the Huntington’s mutation, not merely in isolated cells.

The cellular centerpiece of the study is a reprogramming technology that has become one of the most powerful tools in human neurodegeneration research. The team took skin fibroblasts from symptomatic Huntington’s disease patients and directly converted them into striatal medium spiny neurons, the very cell type that degenerates in patients. This approach, often called direct neuronal reprogramming, bypasses stem cells and preserves age-associated signatures of the donor cells, which is critical for a disease whose onset is so tightly linked to aging. These patient-derived HD-MSNs displayed aberrant translation patterns along their neurites, the long processes that neurons use to communicate—evidence that the protein-synthesis defect is not a diffuse, whole-cell phenomenon but one that strikes at the subcellular compartments where neuronal health is maintained.

When the researchers treated these patient-derived neurons with Raphin1, the effects cascaded across nearly every measure of disease biology they examined. The aberrant translation phenotype along the neurites was reduced, as were the burdens of mutant HTT aggregates—the characteristic protein clumps that define the disorder. The drug also ameliorated disease-associated transcriptional changes, indicating that correcting the translation defect reaches upstream into gene expression programs that have gone awry. Most importantly, Raphin1 prevented neuronal death, the endpoint that matters most for any future therapy. The genetic experiments reinforced the pharmacological ones: knocking down R15B protected the HD-MSNs, while overexpressing it made the disease phenotypes worse. That dose-dependent relationship—less R15B is protective, more R15B is harmful—is exactly the pattern one would expect if R15B is a genuine driver of the disease process rather than a correlate.

The second half of the story adds a layer of regulatory elegance. The researchers found that miR-196a, a microRNA that directly targets human R15B messenger RNA and suppresses its translation, declines in an age-dependent manner in both the human striatum and the reprogrammed medium spiny neurons. MicroRNAs are short regulatory RNAs that fine-tune gene expression after transcription, and their gradual loss with age is an emerging theme in the biology of aging tissues. Here, the declining miR-196a provides a mechanistic explanation for the rising R15B: as the brake on R15B production is released over the decades, protein synthesis regulation drifts, and the vulnerable striatal neurons lose another layer of protection against the mutant protein. The two arms of the study—aging-driven upregulation of R15B and age-dependent loss of its microRNA brake—converge on the same node from opposite directions.

That convergence immediately suggests a therapeutic strategy, and the team tested it. When they overexpressed miR-196a in the disease models, levels of mutant HTT aggregation dropped. Restoring a single age-eroded microRNA was sufficient to reduce the accumulation of the toxic protein species at the heart of the disease. The miR-196a–R15B axis thus emerges as a coherent regulatory circuit: a microRNA that restrains a translation regulator, whose age-related weakening permits the proteostasis failures that characterize Huntington’s disease. Because the axis was validated across diverse models—human postmortem striatal tissue, a transgenic mouse model, and patient-derived reprogrammed neurons—and across diverse phenotypes, from translation patterns to aggregation to cell survival, it stands on unusually broad evidentiary footing for a newly identified disease modifier.

The implications reach beyond Huntington’s disease itself. Huntington’s is one of several adult-onset polyglutamine disorders, and the broader principle—that age-dependent changes in translation control can act as disease modifiers in the vulnerable neurons of the aging brain—may apply to other neurodegenerative conditions in which protein misfolding accumulates over decades. The study also highlights the strategic value of directly reprogrammed patient neurons, which retain the aging biology that conventional stem-cell-derived models often erase. For a field that has endured repeated disappointments in clinical trials, including setbacks for antisense approaches targeting mutant HTT itself, the identification of a druggable modifier downstream of the mutation offers a complementary path: rather than attacking the mutant gene directly, one can target the cellular vulnerabilities that determine when and how severely the mutation strikes.

Considerable work remains before these findings translate to patients. Raphin1’s rescue was demonstrated in mice, and the safety, pharmacokinetics, and delivery of R15B inhibition or miR-196a restoration in humans are open questions. The published version of the study, which appeared online on 26 September 2026 as a peer-reviewed accepted manuscript, will be subject to further editorial refinement. But the conceptual advance is clear and consequential. Huntington’s disease has always carried its trigger from birth, yet its devastation unfolds on a clock set by aging. By identifying a PPP1R15B–miR-196a node where that clock is read out in the striatum—and by showing that intervening at that node rescues deficits in animals and protects patient-derived neurons—the researchers have converted a decades-old mystery about disease onset into a concrete, testable target. In the search for the first disease-modifying therapy for Huntington’s disease, the age-dependent biology of protein synthesis has just moved to the top of the list of places to look.

Subject of Research: Age-dependent translation regulation via the PPP1R15B–miR-196a axis as a modifier of Huntington's disease

Article Title: Age-dependent alterations in human striatum identify a PPP1R15B-miR-196a node as a modifier of Huntington’s disease

Article References: Church, V. A., Krzyzosiak, A., Miao, B., Chen, S., Walker, C. K., Kwon, J.-S., Dahiya, S. L., Wang, L., Al-Dalahmah, O., Zhang, B., Victor, M. B., Bertolotti, A., & Yoo, A. S. (2026). Age-dependent alterations in human striatum identify a PPP1R15B-miR-196a node as a modifier of Huntington’s disease. Nature Communications. https://doi.org/10.1038/s41467-026-78010-0

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78010-0

Keywords: Huntington's disease, striatum, PPP1R15B, miR-196a, translation regulation, proteostasis, neurodegeneration, aging, Raphin1, medium spiny neurons, direct neuronal reprogramming, mutant huntingtin

The team focused on the mitochondrial calcium uniporter, or MCU, a channel protein embedded in the inner mitochondrial membrane that ferries calcium ions from the cytosol into the mitochondrial matrix. In mammals, the MCU complex includes pore-forming MCU proteins regulated by accessory components called MICU and EMRE, and decades of work have established that mitochondrial calcium homeostasis is essential for energy production, cell survival, and the decision between life and death. Plants possess their own family of MCU proteins: Arabidopsis carries six putative MCU orthologs, each with a conserved transmembrane domain, a pore loop, and a signature DVME sequence. Previous studies had shown that MCU1, MCU2, MCU3, and MCU5 localize to mitochondria, while MCU6 can target both mitochondria and chloroplasts, and that a triple mutant lacking MCU1, MCU2, and MCU3 shows reduced calcium uptake in roots. What remained unknown was what happens to the entire cell when this calcium gatekeeping system is disturbed.

To answer that question, the researchers first confirmed where the six MCU proteins reside and when they are active. Using fluorescent YFP tags in stable transgenic plants, they observed that the MCU proteins colocalize with mitochondrial markers in leaf and root cells. GUS staining revealed tissue-specific expression patterns: all six genes are active in the root stele, MCU3 is highly expressed in the root apex and cortex, MCU6 dominates the basal meristem, and MCU3, MCU4, and MCU6 are expressed in guard cells. This map of expression hinted that different MCU family members might play specialized roles in different tissues, but also that they share a common job as mitochondrial calcium channels.

The critical technical advance came from genetics. Because the six MCU genes are functionally redundant, the team crossed single mutants to build a sextuple knockdown line, mcu1-6, in which all six genes are expressed at reduced levels. They also created plants that massively overexpress MCU2, with one line showing a ninefold increase in transcript abundance. To watch calcium dynamics in real time, they targeted the calcium-sensitive luminescent reporter aequorin to the mitochondrial matrix and to the cytosol, then challenged seedlings with mannitol, which mimics drought-induced osmotic stress, and sodium chloride, which imposes salt stress. The results were unambiguous. Overexpressing MCU2 amplified the mitochondrial calcium surge, producing higher peak amplitudes and larger response curves, while the sextuple mutant blunted the response, reducing peak amplitudes by an average of 21 percent under mannitol and 26 percent under salt. Crucially, cytosolic calcium signals were unchanged in both lines, demonstrating that MCUs specifically tune mitochondrial calcium uptake without substantially buffering the cytosolic calcium wave that sweeps through stressed cells.

With the calcium phenotype established, the researchers turned to transcriptomics to see how the cell responds. They compared gene expression in the MCU2 overexpression line and the sextuple mutant against two reference conditions: untreated wild type and wild type treated with antimycin A, a drug that blocks the mitochondrial electron transport chain and classically induces the mitochondrial retrograde response. The comparison produced a surprise. Both MCU-perturbed genotypes activated a broad transcriptional program affecting mitochondrial proteostasis—genes encoding mitoribosomal proteins, oxidative phosphorylation complex subunits, the mitochondrial protein import machinery, and matrix proteases were all upregulated. Chaperone genes from four different compartments were induced as well: mitochondrial Hsp70 proteins, cytosolic chaperones, endoplasmic reticulum chaperones, and chloroplast chaperones. Western blots confirmed that mtHsp70 protein accumulated in the overexpression and knockdown lines. None of this multi-compartment chaperone induction appeared in antimycin-treated plants, and the alternative oxidase genes that normally mark the antimycin response stayed silent in the MCU mutants. In other words, disturbing mitochondrial calcium homeostasis triggers a stress program that is fundamentally different from the well-known retrograde response to respiratory chain damage.

The team interprets this pattern as the simultaneous activation of multiple compartment-specific unfolded protein responses. When proteins fail to fold properly in the mitochondrial matrix, the cell does not merely repair the mitochondrion; it appears to mobilize quality-control machinery in the cytosol, the ER, and the chloroplast as well. The researchers suggest that the underlying trigger is likely proteotoxic stress caused by disturbed mitochondrial translation. Supporting this idea, immunoblots showed that mitochondrially encoded subunits of respiratory complexes III, IV, and V—COB, COX1, ATP4, and ATP8—were reduced in the MCU-perturbed plants, while some nuclear-encoded subunits accumulated, creating a stoichiometric imbalance between the two genomes that supply the respiratory chain. This kind of mitonuclear protein imbalance is a classic activator of the mitochondrial unfolded protein response in animals, and the plant transcriptional profile resembled the interorganellar proteostasis program described in yeast, suggesting deep evolutionary conservation of this alarm system.

But the story did not end with transcription. Quantitative mass spectrometry of the proteome revealed that roughly half of the differentially abundant proteins in the sextuple mutant did not follow their transcript levels. Most strikingly, of the 194 cytosolic ribosomal protein genes whose abundance changed, about 58 percent showed reduced protein despite elevated mRNA. The same paradox appeared for chloroplast and mitochondrial ribosomal proteins and for pentatricopeptide repeat proteins, tetratricopeptide repeat proteins, and pseudouridine synthases—proteins that perform RNA editing and translation inside organelles. To investigate this apparent post-transcriptional repression, the researchers performed polysome profiling, separating actively translated mRNAs on polysomes from poorly translated ones on monosomes. While antimycin treatment caused a dramatic global shift from polysomes to monosomes, the MCU-perturbed plants showed only a mild global shift. Instead, translational efficiency analysis revealed a highly selective repression: genes involved in mitochondrial RNA metabolism and RNA modification lost translational efficiency in both the overexpression line and the sextuple mutant, with about 81 percent of RNA modification transcripts showing low translational efficiency. More than half of all transcriptionally induced cytosolic ribosomal protein mRNAs were also translationally repressed.

This selective translation program points to specific molecular effectors. In mammalian cells, the kinase GCN2 phosphorylates the translation initiation factor eIF2α to dampen protein synthesis during stress, while the TOR pathway senses energy status. The proteomic and immunoblot data told an unexpected tale: in the MCU-perturbed plants, eIF2α protein abundance and its phosphorylated form were both reduced, along with several translation initiation components, while TOR and the energy-sensing kinases KIN10 and KIN11 were largely unaffected. Antimycin treatment produced the opposite signature—increased KIN10 and KIN11 phosphorylation and reduced TOR, with no change in eIF2α. The authors propose that these two pathways mediate distinct types of mitochondrial stress: the TOR-S6K energy-sensing module handles the short-term, acute crisis caused by electron transport chain poisoning, whereas the eIF2α pathway manages the long-term, mild proteotoxic stress of chronic calcium imbalance. Counterintuitively, reducing eIF2α phosphorylation may be protective, preventing a catastrophic shutdown of protein synthesis during prolonged stress—an adaptive mechanism recently proposed in mammalian cells that now appears to operate in plants as well.

The physiological consequences of this molecular storm were visible to the naked eye. Plants with impaired MCU-controlled calcium homeostasis grew more slowly, with reduced leaf area that correlated with MCU2 expression levels in the overexpression lines. They also senesced prematurely, yellowing their older leaves weeks before wild type plants, and the timing of senescence tracked MCU2 dosage. Under osmotic stress induced by mannitol, both the overexpression lines and the sextuple mutant were significantly more sensitive than wild type, with markedly reduced fresh weight. These phenotypes establish a direct link between mitochondrial calcium homeostasis and the core stress biology traits of growth, aging, and stress resistance, and they suggest that the cross-compartmental proteostatic response is not merely a curiosity of gene expression but a determinant of plant fitness.

The study does have acknowledged limitations. The aequorin reporter lacks the sensitivity to resolve basal calcium levels or subtle changes after antimycin treatment, so modest differences in resting mitochondrial calcium cannot be excluded. The upstream regulators of MCU-mediated calcium signaling remain undefined, and future work with established calcium influx mutants such as osca and moca1 will be needed to position the uniporters within the broader calcium signaling hierarchy. The detailed molecular analysis also focused on a single high-expression MCU2 overexpression line, leaving open the possibility that individual MCU isoforms have distinct intrinsic activities. Even so, the findings provide a compelling new framework: mitochondrial calcium homeostasis, mitochondrial translation, and cellular proteostasis are woven together through an interconnected organelle quality control network that integrates transcriptional activation with selective translational repression. As climate change intensifies drought and salinity stress on crops, understanding and potentially engineering this calcium-triggered proteostatic alarm could offer new genetic targets for breeding more resilient plants.

Subject of Research: Mitochondrial calcium homeostasis and cross-compartmental proteostatic signaling in Arabidopsis

Article Title: Perturbation of mitochondrial Ca2+ homeostasis activates cross-compartmental proteostatic response in Arabidopsis

Article References: Perturbation of mitochondrial Ca2+ homeostasis activates cross-compartmental proteostatic response in Arabidopsis. (n.d.). https://doi.org/10.1007/s44154-026-00314-4

Image Credits: AI Generated

DOI: 10.1007/s44154-026-00314-4

Keywords: mitochondria, calcium signaling, mitochondrial calcium uniporter, Arabidopsis, unfolded protein response, proteostasis, retrograde signaling, eIF2α, translation regulation, plant stress, ribosomal proteins, senescence

The appeal of using light as a regulatory input is easy to understand. Unlike drugs or small molecules, light can be applied instantly, confined to a specific region, and tuned in intensity without chemically perturbing the cell. Optogenetic circuits built from photosensitive proteins have transformed neuroscience, allowing researchers to map and manipulate neural activity with millisecond precision. But most of these circuits operate at the level of transcription, controlling whether a gene is read into messenger RNA in the first place. Translation, the step in which ribosomes convert mRNA into protein, offers an even more direct and immediate handle on protein levels, and it is the step that cells themselves regulate most heavily during stress, differentiation, and disease.

In living cells, that translational control is largely exerted by RNA-binding proteins, or RBPs, which latch onto specific sequences in messenger RNAs and either block or boost their translation. During epithelial-mesenchymal transition, for example, the RNA-binding protein RBFOX2 is enabled while ESRP1 is disabled, collectively raising the output of mesenchymal-related mRNAs and suppressing epithelial-related ones. Mimicking this kind of opposing, coordinated regulation with a synthetic device has been the missing piece. The HKUST team, led by Yi Kuang, set out to build a platform in which a single light input would activate one RNA-binding protein while simultaneously preventing the formation of another, allowing two different target mRNAs to be regulated in opposite directions at once.

The core of the design is a clever inversion of a standard optogenetic trick. The researchers began with a split intein, a pair of protein fragments derived from the DnaE intein of the cyanobacterium Nostoc punctiforme that spontaneously stitch themselves together and splice out, fusing whatever proteins are attached to their ends. Normally, light-induced dimerization is used to bring protein fragments together. Here, the team did the opposite: they fused one half of the intein to the blue-light dimerizing protein pMag, and the other half to its partner nMag, but inserted a rigid synthetic alpha-helical spacer of about 39.7 angstroms between the intein fragment and pMag. In the dark, the intein halves find each other and splice normally. Under blue light, pMag and nMag dimerize and physically drag the intein halves apart, holding them beyond the reach of the spacer and blocking splicing altogether.

The team validated the concept in HEK293T cells using fluorescent reporters. When cells expressing the two fusion proteins were kept in the dark, the fluorescent signals swapped localization, confirming that the intein had spliced and conjugated the proteins as intended. Western blot analysis sharpened the picture: dark-incubated cells showed a dominant band at 18.3 kilodaltons, the expected spliced product, accounting for 67.6 percent of the signal, while light-exposed cells showed a dominant band at 36.4 kilodaltons, the unspliced precursor, at 71.4 percent. Removing the spacer abolished the light response entirely, with splicing proceeding under both conditions, proving that the rigid helix was the element converting photodimerization into inhibition. The chosen light intensity of roughly 3.75 milliwatts per square centimeter caused no measurable loss of cell viability.

Crucially, the Light-OFF system proved orthogonal to an existing Light-ON intein system based on the light-oxygen-voltage (LOV) sensing domain, which assembles a different engineered intein pair, NpuM, under the same blue light. When both systems were placed in the same cells, one driving reconstitution of split sfGFP under light and the other driving reconstitution of split mCherry in the dark, the two fluorescent outputs cleanly inverted between conditions. sfGFP signal under light reached levels about 4.5-fold higher than in the dark, while mCherry in the dark was roughly twice the light-condition level. The researchers also showed that the Light-OFF mCherry output could be cycled: switching light and dark every 24 hours over five days made the mCherry signal repeatedly appear and disappear without harming the cells.

With the light-sensing machinery in hand, the team turned to the harder problem of engineering the RNA-binding proteins themselves. They chose two widely used model RBPs, the MS2 bacteriophage coat protein (MCP) and the PP7 coat protein (PCP), which bind distinct RNA aptamers and are workhorses for tracking and manipulating RNA in living cells. When bound to aptamers placed in the 5-prime untranslated region of a reporter mRNA, these proteins suppress translation. The challenge was that split inteins prefer particular amino acids at the splicing junction, and the flexible random-coil regions of MCP and PCP did not naturally offer suitable split sites. The researchers inserted cysteine residues at engineered positions and used AlphaFold 3 to simulate whether each candidate split pair would reconstitute into a structure resembling the original protein, screening candidates by template modeling score and root-mean-square deviation before ever testing them in cells.

The simulations paid off. Split MCP with a cysteine inserted at the 38/39 position and split PCP split at 36/37 proved the most potent, each reconstituting into functional repressors that bound their cognate aptamers and suppressed reporter expression. The team then assembled the full bidirectional photoriboswitch: light induces formation of PCP, which suppresses an EGFP reporter bearing the PP7 aptamer, while darkness allows formation of MCP, which suppresses an iRFP reporter bearing the MS2 aptamer. In cells carrying the full device, the EGFP-to-iRFP ratio shifted by more than 4.3-fold between light and dark conditions, and the platform performed similarly in HeLa cells, with a 6.7-fold shift, demonstrating that the effect is not confined to a single cell line.

Perhaps most strikingly, the platform could be flipped from repression to activation. Many natural RNA-binding proteins enhance translation rather than block it, and the team mimicked this by fusing the VPg translation-promoter motif, derived from a viral protein genome-linked factor, onto the split RBP fragments, while fitting the reporter mRNAs with a translation-deficient cap. Now, light-induced formation of PCP-VPg localized the enhancer onto the EGFP switch and boosted its output, while darkness enabled MCP-VPg to upregulate the iRFP switch. The light-to-dark ratio shift in this configuration exceeded 81.7-fold, a dramatic demonstration that the same architectural principle can be adapted to opposing modes of translational control simply by swapping the functional domain attached to the reconstituted protein.

The authors are candid about the current limitations. Blue light, the input used throughout the study, penetrates tissue poorly and can cause DNA damage, so extending the platform to red or near-infrared sensing pairs such as BphP1/QPAS1 will be essential for any move beyond cultured cells. The system also produces irreversible RBP formation, since intein splicing cannot be undone, although natural protein degradation and dilution during cell growth limit the duration of the effect and allow repeated light-dark cycles of regulation. And the demonstration so far regulates two model reporter mRNAs; extending the approach to multiple physiologically relevant transcripts remains future work. Even so, the design principles on display, using reversible photodimerization to gate irreversible protein assembly and using computational structure prediction to engineer split points where none naturally exist, offer a genuinely expandable foundation. As RNA-based therapeutics and synthetic mRNA circuits mature, tools that can dial protein production up and down with nothing more than light are likely to find eager users, from basic researchers dissecting gene regulation to engineers building cell therapies that respond to optical commands.

Subject of Research: A bidirectional light-controlled riboswitch for regulating translation of synthetic mRNAs in mammalian cells

Article Title: Bidirectional photoriboswitch for translational regulation in mammalian cells

Article References: Hu, Y., Li, C. Y., Fu, L., Sun, Y., Zhang, M., Yau, T. M., Xiong, C., Shi, P., & Kuang, Y. (2026). Bidirectional photoriboswitch for translational regulation in mammalian cells. iScience, 29(10), Article 117671. https://doi.org/10.1016/j.isci.2026.117671

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117671

Keywords: synthetic biology, optogenetics, photoriboswitch, translation regulation, RNA-binding proteins, split intein, mRNA, blue light, AlphaFold 3, mammalian cells, gene expression control, HKUST

Inherited retinal dystrophies are a leading cause of irreversible blindness worldwide, and retinitis pigmentosa, the most common form, affects an estimated 2.5 million people. More than 100 causative genes have been identified, yet between 30 and 50 percent of cases still lack a genetic diagnosis, and the observation of incomplete penetrance hints that factors beyond DNA sequence are at work. Epigenetic mechanisms, which modulate gene expression without altering the genome, have increasingly come into focus in ocular disease. Among these, m6A stands out as the most abundant internal modification in eukaryotic messenger RNA, deposited by writer enzymes, removed by erasers such as FTO and ALKBH5, and interpreted by reader proteins that influence splicing, export, stability, and translation.

METTL16 is a relative newcomer to the m6A field. Unlike the well-known METTL3/METTL14 complex, it recognizes a specific motif, UACAGARAA, within structured RNA contexts, and its validated substrates include MAT2A mRNA, which it regulates to maintain cellular levels of the universal methyl donor S-adenosylmethionine, and U6 snRNA, a small nuclear RNA at the heart of the splicing machinery. METTL16 methylates U6 at position A43 within the ACAGAGA sequence that base-pairs with the 5′ splice site of introns during pre-mRNA splicing. Work in fission yeast, roundworms, plants, and human cells has shown that losing this modification impairs 5′ splice site recognition. Intriguingly, dominant mutations in U6 snRNA have recently been linked to autosomal dominant retinitis pigmentosa, and those variants cluster in regions that contact spliceosome components such as PRPF3, PRPF8, and PRPF31, proteins that are themselves mutated in RP.

To probe METTL16’s role in the retina, the team, led by Jiangbo Ren, Wenjing Liu, and colleagues, generated rod-specific Mettl16 knockout mice by crossing Mettl16-floxed animals with RHO-Cre mice, in which the recombinase is active only in rods. The resulting RKO mice showed efficient excision of the targeted exon and a marked reduction of METTL16 protein in the retina. Single-cell RNA sequencing data from the Human Protein Atlas had already indicated that METTL16 is broadly expressed across retinal cell types, with notable enrichment in rods, making the knockout strategy well suited to testing its function in the cells most vulnerable to retinitis pigmentosa.

The physiological consequences were swift and measurable. Electroretinograms recorded at one month of age revealed that scotopic responses, which reflect rod function, were severely blunted: a-wave and b-wave amplitudes were reduced by roughly 54 and 55 percent, respectively, compared with littermate controls. Cone-mediated photopic responses, by contrast, were largely preserved at this stage, pointing to a rod-first pattern of degeneration. Behavioral assays corroborated the electrophysiology. In a light-dark box test, RKO mice spent only about 39 percent of their time and traveled about 42 percent of their distance in the dark chamber, unlike control mice, which normally prefer darkness. Their optomotor response, a reflexive head movement that tracks rotating visual gratings, dropped to 1.56, well below the values of 2.0 or higher seen in controls.

Under the microscope, the story continued. At postnatal day 20, retinal architecture looked normal, but by day 30 the outer nuclear layer and outer segments of RKO retinas were visibly thinning, and by day 40 the outer nuclear layer had lost roughly 40 percent of its thickness relative to controls. Immunofluorescence showed that key outer segment proteins, including rhodopsin, PRPH2, GRK1, PDE6B, and CNGA1, were markedly reduced in abundance even though their localization within the photoreceptor was not disrupted. Signs of degenerative stress were everywhere: Müller glia became reactive, microglia adopted an amoeboid morphology and invaded the outer nuclear layer, and TUNEL staining detected apoptotic nuclei among the photoreceptors. Cones, meanwhile, showed only delayed involvement, with reduced M-opsin-positive cells appearing by day 40.

To trace the molecular roots of this collapse, the researchers integrated RNA sequencing with quantitative proteomics on one-month-old retinas. Among the genes concordantly downregulated at both the transcript and protein levels, Gene Ontology and KEGG analyses pointed squarely at photoreceptor development, photoreceptor cilia, inner and outer segments, visual perception, and the phototransduction cascade. Five established retinitis pigmentosa genes emerged from this analysis: Tulp1, Cnga1, Pde6g, Crb1, and Prcd. Four of them showed significant differential expression at both levels after correction for multiple testing, and the reductions were confirmed by RT-qPCR and Western blotting. The metabolic arm of the analysis revealed perturbations in the S-adenosylmethionine pathway as well, with Mat2a mRNA, a direct METTL16 substrate, reduced in knockout retinas, and Csad, a key enzyme of taurine biosynthesis, markedly decreased.

The mechanistic core of the paper lies in splicing. Using a single-base elongation and ligation-based qPCR assay called SELECT on purified U6 snRNA, the team confirmed that m6A at position A43 was reduced in knockout retinas. Transcriptome-wide analysis with rMATS then revealed extensive alternative splicing changes, with skipped exons as the predominant event class. Sequence analysis of affected 5′ splice sites showed a telling pattern: sites whose usage decreased in knockout retinas were enriched for adenosine at the +4 position, the very nucleotide engaged by methylated U6, and carried an RAG motif across the U6-interacting positions, whereas sites with increased usage favored stronger U5 snRNA base pairing and non-adenine nucleotides at +4. Crucially, aberrant splicing was already detectable at postnatal day 20, before any overt cell loss. Both Tulp1 and Pde6g, two established retinal dystrophy genes, showed increased exon skipping, and the affected donor sites shared the conserved //GURAG motif previously implicated in METTL16 loss in plants and worms. MeRIP-seq showed no change in m6A enrichment on the Tulp1 and Pde6g transcripts themselves, consistent with a U6-dependent mechanism rather than direct methylation of the mRNAs. The Tulp1 exon 4-skipped transcript is predicted to encode an in-frame deletion of 51 amino acids, and immunostaining revealed disrupted ribbon synapse architecture in knockout retinas, echoing the synaptic defects known from Tulp1 knockout mice.

The study also documented METTL16’s influence beyond the nucleus. MeRIP-seq identified Tor1b and Nlgn2 as candidate direct m6A targets, with reduced methylation in their 3′ untranslated regions and reduced expression in knockout retinas; luciferase reporter assays showed that wild-type METTL16 enhanced reporters bearing the wild-type 3′ UTRs but not motif-mutated versions, and a catalytic-domain-deficient METTL16 mutant failed to do so. In photoreceptor-derived 661W cells, loss of METTL16 accelerated the decay of both transcripts, indicating effects on mRNA stability. Meanwhile, immunoprecipitation coupled with mass spectrometry revealed that retinal METTL16 associates with translation factors including PURA, PABPC1, and EIF3B, and with the splicing factors SF3B1 and SF3B3. SUnSET assays and polysome profiling showed that Mettl16 knockdown reduced global translation efficiency in 661W cells, and polysome analysis confirmed diminished translational efficiency of phototransduction genes such as Cep164, Rpgr, Prph2, and Cnga1, whose mRNA levels were unchanged even as their proteins declined.

The authors are careful to note the limitations: most molecular analyses used bulk retinal tissue, which can blur cell-type-specific effects and mix primary METTL16-dependent events with secondary degenerative changes, and the mechanistic work relied on the 661W cell line because mature rods are difficult to manipulate in vitro. Catalytically dead rescue experiments and ribosome profiling will be needed to determine whether the translational role depends on methyltransferase activity. Even so, the picture that emerges is striking. METTL16, working in both the nucleus and the cytoplasm, appears to safeguard photoreceptors on at least three fronts: by methylating U6 snRNA to preserve splicing fidelity in dystrophy genes, by stabilizing specific m6A-marked transcripts, and by supporting the translation of the proteins that build the light-sensing machinery. Given that mutations in U6 snRNA and multiple spliceosome components cause retinitis pigmentosa in humans, the study suggests that RNA processing defects may be a broader and previously underappreciated theme in photoreceptor disease, one that could eventually inform diagnostic and therapeutic strategies for the many patients whose blindness still has no genetic explanation.

Subject of Research: The role of the m6A methyltransferase METTL16 in photoreceptor survival and retinal degeneration

Article Title: METTL16 maintains photoreceptor integrity via splicing fidelity, mRNA stability, and translational regulation

Article References: Ren, J., Liu, W., Zou, R., Sun, K., Yang, M., Zhu, X., & Yang, Z. (2026). METTL16 maintains photoreceptor integrity via splicing fidelity, mRNA stability, and translational regulation. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.09.012

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.09.012

Keywords: METTL16, m6A, photoreceptors, retinitis pigmentosa, U6 snRNA, alternative splicing, RNA methylation, retinal degeneration, translation regulation, Tulp1, Pde6g, epitranscriptomics